Genentech Says Lucentis DME Product Will Ship Shortly
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves lower, monthly 0.3 mg dose of injectable Lucentis for diabetic macular edema, the regimen Genentech had suggested was most appropriate. Questions remain about the commercial picture, considering competition from the similar but much cheaper Avastin.
You may also be interested in...
Keeping Up With Lucentis: Regeneron’s Eylea Adds Diabetic Retinopathy Claim
FDA approval of supplemental indication for aflibercept brings intravitreal injection’s label in line with that of Genentech’s ranibizumab; Eylea’s dosing advantage and positive data from a recent head-to-head study are likely to put more pressure on Lucentis sales.
KalVista’s Novel DME Approach Moves To Clinical Trials
Britain’s KalVista believes it is pioneering the use of kallikrein inhibitors for diabetic macular edema, including orally active derivatives, as it moves its lead compound into U.S. clinical trials.
Roche Considers Moving Two Drugs Into Phase III, Drops Early-Stage Alzheimer’s Compound In Strong 3rd Quarter
Roche is moving into Phase III with a Lucentis successor, lampalizumab, in ophthalmology, but has dropped development of a Phase I BACE inhibitor for Alzheimer’s disease, the company announced during a third-quarter earnings update, which highlighted pipeline tweaks amid comparatively strong product sales.